These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 22239497)

  • 1. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.
    Stickel F; Helbling B; Heim M; Geier A; Hirschi C; Terziroli B; Wehr K; De Gottardi A; Negro F; Gerlach T
    J Viral Hepat; 2012 Feb; 19(2):77-87. PubMed ID: 22239497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
    Alavian SM; Tabatabaei SV; Behnava B
    J Viral Hepat; 2012 Feb; 19(2):88-93. PubMed ID: 22239498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
    Orāşan O; Cozma A; Rednic N; Sâmpelean D; Pârvu A; Petrov L
    Rom J Intern Med; 2009; 47(3):217-25. PubMed ID: 20446436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualisation of antiviral therapy for chronic hepatitis C.
    Teoh NC; Farrell GC; Chan HL
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1206-16. PubMed ID: 20594246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
    Clark PJ; Aghemo A; Degasperi E; Galmozzi E; Urban TJ; Vock DM; Patel K; Thompson AJ; Rumi MG; D'Ambrosio R; Muir AJ; Colombo M
    J Viral Hepat; 2013 Dec; 20(12):858-66. PubMed ID: 24304455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
    Sharvadze L; Tsertsvadze T; Gochitashvili N; Kakabadze T; Dolmazashvili E
    Georgian Med News; 2006 Aug; (137):62-5. PubMed ID: 16980747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
    Ancel D; Amiot X; Chaslin-Ferbus D; Hagege I; Garioud A; Girot R; Pol S; Grange JD
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):726-9. PubMed ID: 19404206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The adherence in the treatment of chronic hepatitis C].
    Pawłowska M; Halota W
    Pol Merkur Lekarski; 2005 Apr; 18(106):469-72. PubMed ID: 16161937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C.
    Borroni G; Cazzaniga M; Andreoletti M; Ceriani R; Guerzoni P; Omazzi B; Pich MG; Prada A; Spinzi G; Terreni N; Salerno F
    J Viral Hepat; 2013 Apr; 20(4):e90-5. PubMed ID: 23490395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
    Berenguer J; von Wichmann MA; Quereda C; Miralles P; Mallolas J; López-Aldeguer J; Alvarez-Pellicer J; De Miguel J; Crespo M; Guardiola JM; Tellez MJ; Galindo MJ; Arponen S; Barquilla E; Bellón JM; González-García J;
    J Antimicrob Chemother; 2011 Dec; 66(12):2843-9. PubMed ID: 21965432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.
    Smith JP
    Pharmacotherapy; 2008 Sep; 28(9):1151-61. PubMed ID: 18752386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.
    Spiegel BM; Chen K; Chiou CF; Robbins S; Younossi ZM
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10):1034-42. PubMed ID: 16234051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of side-effects.
    Rosa I
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S69-74. PubMed ID: 22248698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
    Durante Mangoni E; Marrone A; Saviano D; Del Vecchio C; Utili R; Ruggiero G
    Antivir Ther; 2003 Feb; 8(1):57-63. PubMed ID: 12713065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of anaemia and other treatment complications.
    Hézode C
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S337-42. PubMed ID: 24091113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
    Gonzalez SA; Jacobson IM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S22-6. PubMed ID: 15468614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms.
    Krishnan SM; Dixit NM
    Antivir Ther; 2012; 17(8):1581-92. PubMed ID: 22809728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.
    Spaan M; Groothuismink ZM; Koning L; Roomer R; Janssen HL; De Knegt RJ; Boonstra A
    Antiviral Res; 2013 Jun; 98(3):469-75. PubMed ID: 23583759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.
    Chang CH; Chen KY; Lai MY; Chan KA
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1623-32. PubMed ID: 12197841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.